Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambridge Laboratories Group, a specialty pharmaceutical company, has announced the launch of Xenazine, the first and only product said to be approved for the treatment of chorea associated with Huntington's disease in the US.
Subscribe to our email newsletter
The product will be sold in the US by Ovation Pharmaceuticals, a biopharmaceutical company, which will market Xenazine to US specialists through its 48-person sales force. The launch follows the acquisition of Cambridge’s original marketing partner, Prestwick Pharmaceuticals, by Biovail in September 2008.
Under the agreement, Biovail will commercialize Xenazine (tetrabenazine) in Canada (marketed under the Nitoman brand name). Biovail will also supply Xenazine to Ovation for a variable percentage of the product’s annual net sales, and will in turn pay a supply price of 50% of net sales to Cambridge.
Ovation will distribute Xenazine via a pharmacy network, designed to both help streamline prescription fulfillment and provide assistance to healthcare professionals, patients and caregivers, including addressing questions about the appropriate use of Xenazine.
Mark Evans, CEO of Cambridge, said: The launch of Xenazine in the US is a significant milestone in Cambridge’s history. We are delighted that Xenazine will be promoted in the US by Ovation, who we believe will be able to maximize Xenazine’s potential in this important market. This is the only treatment for what is a devastating disease and we are pleased that patients finally have a treatment to help alleviate their debilitating symptoms.